The stock of Adverum Biotechnologies Inc (ADVM) has gone down by -11.58% for the week, with a 3.62% rise in the past month and a -57.67% drop in the past quarter. The volatility ratio for the week is 3.15%, and the volatility levels for the past 30 days are 5.83% for ADVM. The simple moving average for the last 20 days is -6.17% for ADVM’s stock, with a simple moving average of -54.43% for the last 200 days.
Is It Worth Investing in Adverum Biotechnologies Inc (NASDAQ: ADVM) Right Now?
Company’s 36-month beta value is 0.70.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADVM is 13.83M, and currently, short sellers hold a 14.06% ratio of that floaft. The average trading volume of ADVM on June 19, 2025 was 334.06K shares.
ADVM) stock’s latest price update
Adverum Biotechnologies Inc (NASDAQ: ADVM)’s stock price has dropped by -1.29 in relation to previous closing price of 2.32. Nevertheless, the company has seen a loss of -11.58% in its stock price over the last five trading days. globenewswire.com reported 2025-06-05 that REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum’s 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4).
Analysts’ Opinion of ADVM
Many brokerage firms have already submitted their reports for ADVM stocks, with Oppenheimer repeating the rating for ADVM by listing it as a “Outperform.” The predicted price for ADVM in the upcoming period, according to Oppenheimer is $25 based on the research report published on June 25, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ADVM reach a price target of $30. The rating they have provided for ADVM stocks is “Buy” according to the report published on April 30th, 2024.
Truist gave a rating of “Buy” to ADVM, setting the target price at $4 in the report published on July 07th of the previous year.
ADVM Trading at -16.63% from the 50-Day Moving Average
After a stumble in the market that brought ADVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.42% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADVM starting from Soparkar Peter, who sale 2,960 shares at the price of $2.00 back on May 15 ’25. After this action, Soparkar Peter now owns 39,154 shares of Adverum Biotechnologies Inc, valued at $5,920 using the latest closing price.
Seyedkazemi Setareh, the CHIEF DEVELOPMENT OFFICER of Adverum Biotechnologies Inc, sale 924 shares at $2.00 during a trade that took place back on May 15 ’25, which means that Seyedkazemi Setareh is holding 13,768 shares at $1,848 based on the most recent closing price.
Stock Fundamentals for ADVM
Current profitability levels for the company are sitting at:
- 46.93 for the present operating margin
- 4.42 for the gross margin
The net margin for Adverum Biotechnologies Inc stands at 48.27. The total capital return value is set at -1.08. Equity return is now at value -127.99, with -65.88 for asset returns.
Based on Adverum Biotechnologies Inc (ADVM), the company’s capital structure generated 0.78 points at debt to capital in total, while cash flow to debt ratio is standing at -1.2.
Currently, EBITDA for the company is -127.27 million with net debt to EBITDA at -0.52. When we switch over and look at the enterprise to sales, we see a ratio of -35.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.57.
Conclusion
In a nutshell, Adverum Biotechnologies Inc (ADVM) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
